http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 25 Aug 2026 16:31:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Lakefront+Biotherapeutic++For%3A+Aug+25/26975179.html si-local-file:///var/storage/secattach/20260825/26975179.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Lakefront+Biotherapeutic++For%3A+Aug+25/26975179.html Tue, 25 Aug 2026 16:31:00 -0400 GLPG LKFT O.00832434 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Lakefront+Biotherapeutic++For%3A+Aug+25/26975179.html si-local-file:///var/storage/secattach/20260825/26975179.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Lakefront+Biotherapeutic++For%3A+Aug+25/26975179.html Tue, 25 Aug 2026 16:31:00 -0400 GLPG LKFT O.00832434 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Lakefront+Biotherapeutic++For%3A+Aug+25/26975179.html si-local-file:///var/storage/secattach/20260825/26975179.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Lakefront+Biotherapeutic++For%3A+Aug+25/26975179.html Tue, 25 Aug 2026 16:31:00 -0400 GLPG LKFT O.00832434 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Lakefront+Biotherapeutic++For%3A+Aug+25/26972580.html si-local-file:///var/storage/secattach/20260825/26972580.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Lakefront+Biotherapeutic++For%3A+Aug+25/26972580.html Tue, 25 Aug 2026 10:29:00 -0400 GLPG LKFT O.00832434 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Lakefront+Biotherapeutic++For%3A+Aug+25/26972580.html si-local-file:///var/storage/secattach/20260825/26972580.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Lakefront+Biotherapeutic++For%3A+Aug+25/26972580.html Tue, 25 Aug 2026 10:29:00 -0400 GLPG LKFT O.00832434 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Lakefront+Biotherapeutic++For%3A+Aug+25/26972580.html si-local-file:///var/storage/secattach/20260825/26972580.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Lakefront+Biotherapeutic++For%3A+Aug+25/26972580.html Tue, 25 Aug 2026 10:29:00 -0400 GLPG LKFT O.00832434 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Lakefront+Biotherapeutic++For%3A+Aug+25/26972562.html si-local-file:///var/storage/secattach/20260825/26972562.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Lakefront+Biotherapeutic++For%3A+Aug+25/26972562.html Tue, 25 Aug 2026 10:26:00 -0400 GLPG LKFT O.00832434 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Lakefront+Biotherapeutic++For%3A+Aug+25/26972562.html si-local-file:///var/storage/secattach/20260825/26972562.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Lakefront+Biotherapeutic++For%3A+Aug+25/26972562.html Tue, 25 Aug 2026 10:26:00 -0400 GLPG LKFT O.00832434 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Lakefront+Biotherapeutic++For%3A+Aug+25/26972562.html si-local-file:///var/storage/secattach/20260825/26972562.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Lakefront+Biotherapeutic++For%3A+Aug+25/26972562.html Tue, 25 Aug 2026 10:26:00 -0400 GLPG LKFT O.00832434 http://www.streetinsider.com/New+Coverage/TD+Cowen+Starts+Lakefront+Biotherapeutics+%28LKFT%29+at+Buy/26957899.html <p>TD Cowen analyst Phil Nadeau initiates coverage on Lakefront Biotherapeutics (NASDAQ: LKFT) with a Buy rating.</p><p>The analyst comments "We are reinstating our Buy rating on LKFT following the completion of Gilead and Lakefront's acquisition of Ouro Medicines. With Lakefront trading at a negative enterprise value, we think the stock is positioned to create shareholder value should BCMAxCD3 TCE gamgertamig be successfully developed, and/or should management execute on additional promising business development opportunities."</p><p>For an analyst ratings summary and ratings history on Lakefront Biotherapeutics <a href="http://www.streetinsider.com/rating_history.php?q=LKFT">click here</a>. For more ratings news on Lakefront Biotherapeutics <a href="http://www.streetinsider.com/stock_lookup_news.php?q=LKFT&amp;type=analyst">click here</a>.</p><p>Shares of Lakefront Biotherapeutics closed at http://www.streetinsider.com/New+Coverage/TD+Cowen+Starts+Lakefront+Biotherapeutics+%28LKFT%29+at+Buy/26957899.html Fri, 21 Aug 2026 05:12:05 -0400 LKFT http://www.streetinsider.com/Analyst+Comments/TD+Cowen+Starts+Lakefront+Biotherapeutics+%28LKFT%29+at+Buy/26957899.html <p>TD Cowen analyst Phil Nadeau initiates coverage on Lakefront Biotherapeutics (NASDAQ: LKFT) with a Buy rating.</p><p>The analyst comments "We are reinstating our Buy rating on LKFT following the completion of Gilead and Lakefront's acquisition of Ouro Medicines. With Lakefront trading at a negative enterprise value, we think the stock is positioned to create shareholder value should BCMAxCD3 TCE gamgertamig be successfully developed, and/or should management execute on additional promising business development opportunities."</p><p>For an analyst ratings summary and ratings history on Lakefront Biotherapeutics <a href="http://www.streetinsider.com/rating_history.php?q=LKFT">click here</a>. For more ratings news on Lakefront Biotherapeutics <a href="http://www.streetinsider.com/stock_lookup_news.php?q=LKFT&amp;type=analyst">click here</a>.</p><p>Shares of Lakefront Biotherapeutics closed at http://www.streetinsider.com/Analyst+Comments/TD+Cowen+Starts+Lakefront+Biotherapeutics+%28LKFT%29+at+Buy/26957899.html Fri, 21 Aug 2026 05:12:05 -0400 LKFT http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+Announces+2026+H1+Results+and+Business+Updates/26954312.html <div class="xn-content"> <p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/cn..chengd" idsrc="xmltag.org" >CHENGDU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 20, 2026</chron></span> /PRNewswire/ -- On <chron>August 19, 2026</chron>, <span value="HongKong:2162" idsrc="xmltag.org" >Keymed Biosciences</span> (HKEX: 02162) announced its interim results for the six months ended <chron>June 30, 2026</chron>. Guided by a clear dual-engine driven strategy, the company demonstrated outstanding execution capabilities: In the domestic market, following the successful commercialization and implementation of medical insurance coverage for the core product Kangyueda, the company's highly qualified in-house marketing team rapidly stepped up its efforts, driving a robust breakthrough in domestic commercialization revenue from "1 to N", and providing the Company with a robust http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+Announces+2026+H1+Results+and+Business+Updates/26954312.html Thu, 20 Aug 2026 10:09:00 -0400 02162 2162 A.00423054 A.24467511 A.50216976 GLPG GLPG LKFT LKFT O.00400076 O.00609993 O.00832434 O.50329372 O.69976832 http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+Announces+2026+H1+Results+and+Business+Updates/26954312.html <div class="xn-content"> <p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/cn..chengd" idsrc="xmltag.org" >CHENGDU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 20, 2026</chron></span> /PRNewswire/ -- On <chron>August 19, 2026</chron>, <span value="HongKong:2162" idsrc="xmltag.org" >Keymed Biosciences</span> (HKEX: 02162) announced its interim results for the six months ended <chron>June 30, 2026</chron>. Guided by a clear dual-engine driven strategy, the company demonstrated outstanding execution capabilities: In the domestic market, following the successful commercialization and implementation of medical insurance coverage for the core product Kangyueda, the company's highly qualified in-house marketing team rapidly stepped up its efforts, driving a robust breakthrough in domestic commercialization revenue from "1 to N", and providing the Company with a robust http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+Announces+2026+H1+Results+and+Business+Updates/26954312.html Thu, 20 Aug 2026 10:09:00 -0400 02162 2162 A.00423054 A.24467511 A.50216976 GLPG GLPG LKFT LKFT O.00400076 O.00609993 O.00832434 O.50329372 O.69976832 http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+Announces+2026+H1+Results+and+Business+Updates/26954312.html <div class="xn-content"> <p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/cn..chengd" idsrc="xmltag.org" >CHENGDU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 20, 2026</chron></span> /PRNewswire/ -- On <chron>August 19, 2026</chron>, <span value="HongKong:2162" idsrc="xmltag.org" >Keymed Biosciences</span> (HKEX: 02162) announced its interim results for the six months ended <chron>June 30, 2026</chron>. Guided by a clear dual-engine driven strategy, the company demonstrated outstanding execution capabilities: In the domestic market, following the successful commercialization and implementation of medical insurance coverage for the core product Kangyueda, the company's highly qualified in-house marketing team rapidly stepped up its efforts, driving a robust breakthrough in domestic commercialization revenue from "1 to N", and providing the Company with a robust http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+Announces+2026+H1+Results+and+Business+Updates/26954312.html Thu, 20 Aug 2026 10:09:00 -0400 02162 2162 A.00423054 A.24467511 A.50216976 GLPG GLPG LKFT LKFT O.00400076 O.00609993 O.00832434 O.50329372 O.69976832 http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+Announces+2026+H1+Results+and+Business+Updates/26954312.html <div class="xn-content"> <p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/cn..chengd" idsrc="xmltag.org" >CHENGDU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 20, 2026</chron></span> /PRNewswire/ -- On <chron>August 19, 2026</chron>, <span value="HongKong:2162" idsrc="xmltag.org" >Keymed Biosciences</span> (HKEX: 02162) announced its interim results for the six months ended <chron>June 30, 2026</chron>. Guided by a clear dual-engine driven strategy, the company demonstrated outstanding execution capabilities: In the domestic market, following the successful commercialization and implementation of medical insurance coverage for the core product Kangyueda, the company's highly qualified in-house marketing team rapidly stepped up its efforts, driving a robust breakthrough in domestic commercialization revenue from "1 to N", and providing the Company with a robust http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+Announces+2026+H1+Results+and+Business+Updates/26954312.html Thu, 20 Aug 2026 10:09:00 -0400 02162 2162 A.00423054 A.24467511 A.50216976 GLPG GLPG LKFT LKFT O.00400076 O.00609993 O.00832434 O.50329372 O.69976832 http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+Announces+2026+H1+Results+and+Business+Updates/26954312.html <div class="xn-content"> <p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/cn..chengd" idsrc="xmltag.org" >CHENGDU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 20, 2026</chron></span> /PRNewswire/ -- On <chron>August 19, 2026</chron>, <span value="HongKong:2162" idsrc="xmltag.org" >Keymed Biosciences</span> (HKEX: 02162) announced its interim results for the six months ended <chron>June 30, 2026</chron>. Guided by a clear dual-engine driven strategy, the company demonstrated outstanding execution capabilities: In the domestic market, following the successful commercialization and implementation of medical insurance coverage for the core product Kangyueda, the company's highly qualified in-house marketing team rapidly stepped up its efforts, driving a robust breakthrough in domestic commercialization revenue from "1 to N", and providing the Company with a robust http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+Announces+2026+H1+Results+and+Business+Updates/26954312.html Thu, 20 Aug 2026 10:09:00 -0400 02162 2162 A.00423054 A.24467511 A.50216976 GLPG GLPG LKFT LKFT O.00400076 O.00609993 O.00832434 O.50329372 O.69976832 http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+Announces+2026+H1+Results+and+Business+Updates/26954312.html <div class="xn-content"> <p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/cn..chengd" idsrc="xmltag.org" >CHENGDU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 20, 2026</chron></span> /PRNewswire/ -- On <chron>August 19, 2026</chron>, <span value="HongKong:2162" idsrc="xmltag.org" >Keymed Biosciences</span> (HKEX: 02162) announced its interim results for the six months ended <chron>June 30, 2026</chron>. Guided by a clear dual-engine driven strategy, the company demonstrated outstanding execution capabilities: In the domestic market, following the successful commercialization and implementation of medical insurance coverage for the core product Kangyueda, the company's highly qualified in-house marketing team rapidly stepped up its efforts, driving a robust breakthrough in domestic commercialization revenue from "1 to N", and providing the Company with a robust http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+Announces+2026+H1+Results+and+Business+Updates/26954312.html Thu, 20 Aug 2026 10:09:00 -0400 02162 2162 A.00423054 A.24467511 A.50216976 GLPG GLPG LKFT LKFT O.00400076 O.00609993 O.00832434 O.50329372 O.69976832 http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+Announces+2026+H1+Results+and+Business+Updates/26954312.html <div class="xn-content"> <p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/cn..chengd" idsrc="xmltag.org" >CHENGDU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 20, 2026</chron></span> /PRNewswire/ -- On <chron>August 19, 2026</chron>, <span value="HongKong:2162" idsrc="xmltag.org" >Keymed Biosciences</span> (HKEX: 02162) announced its interim results for the six months ended <chron>June 30, 2026</chron>. Guided by a clear dual-engine driven strategy, the company demonstrated outstanding execution capabilities: In the domestic market, following the successful commercialization and implementation of medical insurance coverage for the core product Kangyueda, the company's highly qualified in-house marketing team rapidly stepped up its efforts, driving a robust breakthrough in domestic commercialization revenue from "1 to N", and providing the Company with a robust http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+Announces+2026+H1+Results+and+Business+Updates/26954312.html Thu, 20 Aug 2026 10:09:00 -0400 02162 2162 A.00423054 A.24467511 A.50216976 GLPG GLPG LKFT LKFT O.00400076 O.00609993 O.00832434 O.50329372 O.69976832 http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+Announces+2026+H1+Results+and+Business+Updates/26954312.html <div class="xn-content"> <p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/cn..chengd" idsrc="xmltag.org" >CHENGDU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 20, 2026</chron></span> /PRNewswire/ -- On <chron>August 19, 2026</chron>, <span value="HongKong:2162" idsrc="xmltag.org" >Keymed Biosciences</span> (HKEX: 02162) announced its interim results for the six months ended <chron>June 30, 2026</chron>. Guided by a clear dual-engine driven strategy, the company demonstrated outstanding execution capabilities: In the domestic market, following the successful commercialization and implementation of medical insurance coverage for the core product Kangyueda, the company's highly qualified in-house marketing team rapidly stepped up its efforts, driving a robust breakthrough in domestic commercialization revenue from "1 to N", and providing the Company with a robust http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+Announces+2026+H1+Results+and+Business+Updates/26954312.html Thu, 20 Aug 2026 10:09:00 -0400 02162 2162 A.00423054 A.24467511 A.50216976 GLPG GLPG LKFT LKFT O.00400076 O.00609993 O.00832434 O.50329372 O.69976832 http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+Announces+2026+H1+Results+and+Business+Updates/26954312.html <div class="xn-content"> <p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/cn..chengd" idsrc="xmltag.org" >CHENGDU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 20, 2026</chron></span> /PRNewswire/ -- On <chron>August 19, 2026</chron>, <span value="HongKong:2162" idsrc="xmltag.org" >Keymed Biosciences</span> (HKEX: 02162) announced its interim results for the six months ended <chron>June 30, 2026</chron>. Guided by a clear dual-engine driven strategy, the company demonstrated outstanding execution capabilities: In the domestic market, following the successful commercialization and implementation of medical insurance coverage for the core product Kangyueda, the company's highly qualified in-house marketing team rapidly stepped up its efforts, driving a robust breakthrough in domestic commercialization revenue from "1 to N", and providing the Company with a robust http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+Announces+2026+H1+Results+and+Business+Updates/26954312.html Thu, 20 Aug 2026 10:09:00 -0400 02162 2162 A.00423054 A.24467511 A.50216976 GLPG GLPG LKFT LKFT O.00400076 O.00609993 O.00832434 O.50329372 O.69976832 http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+Announces+2026+H1+Results+and+Business+Updates/26954312.html <div class="xn-content"> <p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/cn..chengd" idsrc="xmltag.org" >CHENGDU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 20, 2026</chron></span> /PRNewswire/ -- On <chron>August 19, 2026</chron>, <span value="HongKong:2162" idsrc="xmltag.org" >Keymed Biosciences</span> (HKEX: 02162) announced its interim results for the six months ended <chron>June 30, 2026</chron>. Guided by a clear dual-engine driven strategy, the company demonstrated outstanding execution capabilities: In the domestic market, following the successful commercialization and implementation of medical insurance coverage for the core product Kangyueda, the company's highly qualified in-house marketing team rapidly stepped up its efforts, driving a robust breakthrough in domestic commercialization revenue from "1 to N", and providing the Company with a robust http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+Announces+2026+H1+Results+and+Business+Updates/26954312.html Thu, 20 Aug 2026 10:09:00 -0400 02162 2162 A.00423054 A.24467511 A.50216976 GLPG GLPG LKFT LKFT O.00400076 O.00609993 O.00832434 O.50329372 O.69976832 http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+Announces+2026+H1+Results+and+Business+Updates/26954312.html <div class="xn-content"> <p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/cn..chengd" idsrc="xmltag.org" >CHENGDU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 20, 2026</chron></span> /PRNewswire/ -- On <chron>August 19, 2026</chron>, <span value="HongKong:2162" idsrc="xmltag.org" >Keymed Biosciences</span> (HKEX: 02162) announced its interim results for the six months ended <chron>June 30, 2026</chron>. Guided by a clear dual-engine driven strategy, the company demonstrated outstanding execution capabilities: In the domestic market, following the successful commercialization and implementation of medical insurance coverage for the core product Kangyueda, the company's highly qualified in-house marketing team rapidly stepped up its efforts, driving a robust breakthrough in domestic commercialization revenue from "1 to N", and providing the Company with a robust http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+Announces+2026+H1+Results+and+Business+Updates/26954312.html Thu, 20 Aug 2026 10:09:00 -0400 02162 2162 A.00423054 A.24467511 A.50216976 GLPG GLPG LKFT LKFT O.00400076 O.00609993 O.00832434 O.50329372 O.69976832 http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+Announces+2026+H1+Results+and+Business+Updates/26954312.html <div class="xn-content"> <p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/cn..chengd" idsrc="xmltag.org" >CHENGDU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 20, 2026</chron></span> /PRNewswire/ -- On <chron>August 19, 2026</chron>, <span value="HongKong:2162" idsrc="xmltag.org" >Keymed Biosciences</span> (HKEX: 02162) announced its interim results for the six months ended <chron>June 30, 2026</chron>. Guided by a clear dual-engine driven strategy, the company demonstrated outstanding execution capabilities: In the domestic market, following the successful commercialization and implementation of medical insurance coverage for the core product Kangyueda, the company's highly qualified in-house marketing team rapidly stepped up its efforts, driving a robust breakthrough in domestic commercialization revenue from "1 to N", and providing the Company with a robust http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+Announces+2026+H1+Results+and+Business+Updates/26954312.html Thu, 20 Aug 2026 10:09:00 -0400 02162 2162 A.00423054 A.24467511 A.50216976 GLPG GLPG LKFT LKFT O.00400076 O.00609993 O.00832434 O.50329372 O.69976832 http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+Announces+2026+H1+Results+and+Business+Updates/26954312.html <div class="xn-content"> <p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/cn..chengd" idsrc="xmltag.org" >CHENGDU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 20, 2026</chron></span> /PRNewswire/ -- On <chron>August 19, 2026</chron>, <span value="HongKong:2162" idsrc="xmltag.org" >Keymed Biosciences</span> (HKEX: 02162) announced its interim results for the six months ended <chron>June 30, 2026</chron>. Guided by a clear dual-engine driven strategy, the company demonstrated outstanding execution capabilities: In the domestic market, following the successful commercialization and implementation of medical insurance coverage for the core product Kangyueda, the company's highly qualified in-house marketing team rapidly stepped up its efforts, driving a robust breakthrough in domestic commercialization revenue from "1 to N", and providing the Company with a robust http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+Announces+2026+H1+Results+and+Business+Updates/26954312.html Thu, 20 Aug 2026 10:09:00 -0400 02162 2162 A.00423054 A.24467511 A.50216976 GLPG GLPG LKFT LKFT O.00400076 O.00609993 O.00832434 O.50329372 O.69976832 http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+Announces+2026+H1+Results+and+Business+Updates/26954312.html <div class="xn-content"> <p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/cn..chengd" idsrc="xmltag.org" >CHENGDU, China</location></span>, <span class="legendSpanClass"><chron>Aug. 20, 2026</chron></span> /PRNewswire/ -- On <chron>August 19, 2026</chron>, <span value="HongKong:2162" idsrc="xmltag.org" >Keymed Biosciences</span> (HKEX: 02162) announced its interim results for the six months ended <chron>June 30, 2026</chron>. Guided by a clear dual-engine driven strategy, the company demonstrated outstanding execution capabilities: In the domestic market, following the successful commercialization and implementation of medical insurance coverage for the core product Kangyueda, the company's highly qualified in-house marketing team rapidly stepped up its efforts, driving a robust breakthrough in domestic commercialization revenue from "1 to N", and providing the Company with a robust http://www.streetinsider.com/Press+Releases/Keymed+Biosciences+Announces+2026+H1+Results+and+Business+Updates/26954312.html Thu, 20 Aug 2026 10:09:00 -0400 02162 2162 A.00423054 A.24467511 A.50216976 GLPG GLPG LKFT LKFT O.00400076 O.00609993 O.00832434 O.50329372 O.69976832